Benefit–risk analysis to decide the indication for allogeneic SCT
The indication is determined on an individual basis for each patient and should be discussed with the patient and his/her family members. GvM, graft-versus-malignancy; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; SCT, stem cell transplantation